Evidence map›Paper›PMID 33925377›Full record

ArticleInternational journal of environmental research and public health2021

Risk Factors for Unfavorable Treatment Outcomes among the Human Immunodeficiency Virus-Associated Tuberculosis Population in Tashkent City, Uzbekistan: 2013-2017.

Sherali Massavirov, Kristina Akopyan, Fazlkhan Abdugapparov, Ana Ciobanu, Arax Hovhanessyan, Mavluda Khodjaeva, Jamshid Gadoev, Nargiza Parpieva

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Tuberculosis Death Epidemiology and Its Associated Risk Factors in Sabah, Malaysia.International journal of environmental research and public health · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Sherali MassavirovDepartment of Phthisiology and Pulmonology of the Tashkent Medical Academy, Tashkent 100109, Uzbekistan.
Kristina AkopyanWHO Regional Office for Europe, DK-2100 Copenhagen, Denmark.ORCID 0000-0003-0177-1870
Fazlkhan AbdugapparovDepartment of Phthisiology and Pulmonology of the Tashkent Medical Academy, Tashkent 100109, Uzbekistan.
Ana CiobanuWHO Regional Office for Europe, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-3260-0348
Arax HovhanessyanWHO Regional Office for Europe, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-7904-9071
Mavluda KhodjaevaDepartment of Phthisiology and Pulmonology of the Tashkent Medical Academy, Tashkent 100109, Uzbekistan.
Jamshid GadoevWorld Health Organization Country Office in Uzbekistan, 16, Tarobiy Street, Tashkent 100100, Uzbekistan.ORCID 0000-0003-3998-5786
Nargiza ParpievaDepartment of Phthisiology and Pulmonology of the Tashkent Medical Academy, Tashkent 100109, Uzbekistan.
Tashkent Medical Academy · UZWorld Health Organization Regional Office for Europe · DKTashkent Pediatric Medical Institute · UZ

Funding

World Health Organization 001
6 · The paper itself

Abstract

Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection poses a growing clinical challenge. People living with HIV have a higher chance of developing TB, and once the disease has progressed, are at greater risk of having unfavorable TB treatment outcomes. Data on TB treatment outcomes among the HIV-associated TB population in Uzbekistan are limited. Thus, we conducted a cohort study among 808 adult patients with HIV-associated TB registered at the Tashkent TB referral hospital from 2013-2017 to document baseline characteristics and evaluate risk factors for unfavorable TB treatment outcomes. The data were collected from medical records and ambulatory cards. About 79.8% of the study population had favorable treatment outcomes. Antiretroviral therapy (ART) coverage at the admission was 26.9%. Information on CD4-cell counts and viral loads were largely missing. Having extrapulmonary TB (aOR 2.21, 95% CI: 1.38-3.53,

Indexed as

CoinfectionHIV InfectionsTuberculosisAdultAntitubercular AgentsCohort StudiesHIVHumansRetrospective StudiesRisk FactorsTreatment OutcomeUzbekistanAntitubercular Agentscentral Asiadiabeteshepatitis CHIVoperational researchopportunistic infectionSORT ITtreatment outcomestuberculosisUzbekistan

Identifiers

PMID33925377
PMCPMC8123775
OpenAlexW3159595080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.